Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Hello, Ramjet, I have an opinion on your question

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154851
(Total Views: 575)
Posted On: 12/03/2024 8:21:59 PM
Posted By: USS JOHNSTON
Re: Ramjet #148386
Hello, Ramjet, I have an opinion on your question -

"Do we have to have new data from the studies and trials outstanding or is there enough for a deal on an indication?"

- but fyi, EVERY opinion I've had on the possibility of a deal has been wrong since March of 2020, i.e., when I bought my first shares @ a SP of $1.03

In short, based on Leronlimab's success with AIDS patients, I think every major biopharma is aware of the molecule's efficacy and safety. And since they're staffed with their own "Ohms," I also believe they are fully aware of our potential across a wide swath of diseases.

But since we sit at 11 cents/share, and since we were at about 30 cents a share just before I bought in back in March 2020, I have to believe there is a deliberate effort to suppress our SP. There is no other molecule like ours, nothing so safe and with so much potential (at least none that I've heard of), so the ONLY thing that makes 11 cents/share possible is deliberate suppression.

Large biopharmas want us to crash and burn, and "they" had enough influence with the FDA to keep a molecule with an absolutely stellar safety profile on a safety hold for 2 years.

So, "is there enough for a deal on an indication?" Absolutely. And when dangerous Alzheimers drugs are approved that do nothing, when Remdesivir was approved that either killed or made patients demonstrably worse?

"They" value profits or people. The suppression of our SP is a crime against the sick and diseased, and I hope, really hope and pray that the new FDA is not like the old FDA.

If we get a believer in LL at the top of the FDA or CDC or NIH or HHS?
Who knows, that might be all it takes.



(7)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us